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Objectives: Given the persistence of post-traumatic stress disorder (PTSD) and its major impact 
on everyday life, it is important to identify effective treatments. In additional to pharmacologi-
cal treatments, psychotherapeutic treatments are also highly effective. The aim of the present 
study was to investigate, among a sample of patients suffering from PTSD, the influence of 
an additional cognitive behavioral therapy (CBT) intervention on their symptoms of PTSD, 
depression, and anxiety, and on autobiographical memory.
Methods: A total of 40 patients suffering from PTSD (mean age: 31.64 years; 78.6% female 
patients) and under psychopharmacological treatment were randomly assigned to an interven-
tion or control condition. The intervention consisted of ten group sessions (one 60–90 minute 
session per week) of CBT. At baseline and 10 weeks later, a series of self-rating and experts’-
rating questionnaires were completed.
Results: Over time, symptoms of PTSD, depression, and anxiety decreased; however, greater 
improvement was observed in the experimental than the control condition. Likewise, as a general 
pattern of results, memory performance improved over time, though again this improvement 
was greater in the experimental condition.
Conclusion: Compared to a control condition, additional CBT improves the treatment of PTSD, 
with respect to both symptoms and autobiographical memory.
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Objectives
Post-traumatic stress disorder (PTSD) is a common psychiatric disorder that may 
occur following a range of experiences including witnessing life-threatening inci-
dents such as in a war zone, natural disasters, terror attacks, and serious car accidents. 
Persistent avoidance of stimuli, slow responses (eg, feelings of isolation and loss of 
personal interests), re-experiencing the trauma (unavoidable recall of the traumatic 
event, nightmares), and increased autonomic stimulation (hyper activity, irritability, 
and sleep disorders) are the main symptoms of this condition, observable shortly 
after onset.1 Whereas not everyone exposed to such life events develops PTSD, in the 
USA, it occurs among 10% of women and 5% of men who were previously exposed 
to such kind of live events.2 Moreover, the life-time risk in the general population 
of developing at least one episode of PTSD is estimated to be 8%–9%.3 In addition 
to flashbacks, nightmares are often reported by those suffering from PTSD. In this 
context, sleep disorders comprise about 70% of the complaints of patients with 
PTSD.4,5 They are also more likely to commit suicide than persons without PTSD.6,7 
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The risk of suicide among those with PTSD is higher 
for people reporting nightmares than for those who do 
not.8 Accordingly, symptoms need to be recognized and 
treated appropriately if they are not to become persis-
tent.9 In addition, patients with PTSD are at high risk of 
developing comorbid psychiatric disorders such as mood, 
anxiety, and substance abuse disorders. Furthermore, the 
high chronicity, severity, and comorbidity of PTSD are 
associated with high levels of functional and psychosocial 
disability,10 and also with dramatic impairments in memory 
and autobiographical memory.11 Accordingly, in the present 
study, we investigated the influence of additional CBT on 
the autobiographical memory of patients with PTSD.
As regards treatment interventions, PTSD can be treated 
both pharmacologically and non-pharmacologically; that is, 
psychotherapeutically. Depending on symptom severity and 
comorbid disorders, pharmacological treatment typically 
involves administration of selective serotonin reuptake 
inhibitors (SSRIs), benzodiazepines, and antipsychotics. 
Diverse medication classes, including antidepressants, anti-
convulsants, antipsychotics and antiadrenergic drugs have 
been used to treat PTSD. Thereby, antidepressants are the 
most used and prescribed medication for PTSD,3 and SSRIs 
are the only class of medication approved for treatment of 
PTSD in the USA. SSRIs seem to be safer and better toler-
ated than other psychotropic medications and many of the 
clinical trials showed that there is evidence of best efficacy 
in reducing PTSD symptoms for this class of medication.3 
SSRIs have shown to be efficient in reducing symptom sever-
ity and in preventing PTSD patients from relapsing, although 
just a few patients (about 60%) respond to treatment and only 
approximately 20%–30% have been fully remitted.12 SSRI 
paroxetine, for example, succeeded in effective reduction 
of symptoms of all three PTSD symptom clusters, namely 
re-experiencing of the trauma, increased arousal, and avoid-
ance of situations that resemble the traumatic event.10 Among 
the empirically-supported psychotherapeutic interventions 
are trauma-focused cognitive behavioral therapy (CBT), 
exposure-based therapy, eye movement desensitization and 
reprocessing,10 stress inoculated training, and CBT.12 Further, 
prolonged exposure is the most researched and best validated 
non-pharmacological treatment for PTSD.3 In the present 
study, we focused on CBT.
Several placebo-controlled trials and meta-analyses 
support the view that these non-pharmacological treatments 
are effective in reducing PTSD symptoms.13 International 
guidelines recommend non-pharmacological treatment 
for all PTSD patients as the first option (Polak et al10) and 
pharmacological treatment as a second option, but no consen-
sus has been achieved on these alternatives so far.3 More spe-
cifically, and contrary to Polak et al,10 Ipser et al14 concluded 
based on a Cochrane review that medication treatments can 
be effective in treating PTSD, and should be considered as a 
part of the treatment of PTSD, with the application SSRIs as 
first-line agents in the pharmacotherapy of PTSD. However, 
we also note that the Institute of Medicine Report concluded 
that there was no evidence that one of the several medication 
classes was effective for treatment of PTSD, while the UK 
National Institute for Clinical Excellence recommended in 
2005 that medications should only be used as a second-line 
treatment for PTSD.3 This may also be due to the much higher 
treatment costs for pharmacotherapies in comparison to psy-
chotherapies, especially in relation to higher expected relapse 
rates with pharmacotherapies.10 Moreover, the efficacy of 
pharmacological treatment for PTSD may also depend on 
the type of symptoms. On the other hand, and apparently 
paradoxically, Mellman et al16 estimated that 77% of PTSD 
patients in a community-based sample received pharmaco-
therapy. This high rate for pharmacotherapy may reflect the 
low availability and accessibility of psychotherapy.10 There 
is also some evidence that those patients who report more 
severe sleep difficulties have poorer treatment outcomes 
with psychotherapy.3
Last, combined pharmacotherapy and psychological 
therapies are especially recommended when patients have 
not responded to either intervention alone,16 and this needs 
to be further examined in future research.18,19
A further issue of PTSD regards memory performance, 
in that one of the most serious and frequent symptoms of 
PTSD is intrusive memories of the traumatic event.20 Since 
PTSD symptoms often persist long after exposure to the 
traumatic event, researchers have given particular attention 
to memory as a key factor in the pathogenesis of the disor-
der.22 Most strikingly, there is evidence that PTSD patients 
show difficulties in retrieval of autobiographical memories.21 
In addition, patients with PTSD tend to report more memories 
related to the traumatic event compared to people without 
PTSD.20 They tend to exhibit difficulties in recalling specific 
memories; producing a so-called “overgeneralized” autobio-
graphical memory.
Furthermore, it is not only autobiographical memories 
that are characterized by overgeneralization. Expectations 
that individuals with PTSD have about imagined future 
events are also characterized by overgeneralization.20 
Overgeneralized autobiographical memory has been 
implicated as an important mechanism underlying the 
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pathogenesis of PTSD, and the close connection between 
overgeneralization in autobiographical memory and in 
thinking about the future seems to be conducive to the 
onset and maintenance of the disorder.22 To summarize, 
PTSD is a severe psychiatric disorder, affecting patients’ 
emotions, behavior, social life, and cognitions. With respect 
to cognitions, memory performance, and more specifically, 
autobiographical memory performance, is impaired. PTSD 
is treated pharmacologically and non-pharmacologically. 
From previous research, we learn that the effect of addi-
tional CBT in combination with psychopharmacological 
treatment is poorly investigated, and in particular that the 
influence of additional CBT on autobiographical memory 
has not so far been investigated. Accordingly, the aims of 
the present study were to investigate the influence of addi-
tional CBT on symptoms of PTSD, depression, and anxiety, 
and on autobiographical memory in patients suffering from 
PTSD, as compared to a control condition. We hold that 
the present study has the potential to expand on previous 
research in that the data from both the case-control design 
and the study targets should add to the current literature 
in an important way.
The following two hypotheses were formulated. First, 
following Hendriksen et al,12 Polak et al10 and others, we 
expected improved symptoms of PTSD, depression, and anxi-
ety in the CBT as compared to the control group. Second, fol-
lowing Brown et al21 we expected that autobiographic memory 
performance would be low at baseline and would improve in 
the treatment as compared to the control group. Additionally, 
given the lack of previous research, we treated exploratory 
potential changes in autobiographical memory as a function of 
domain (semantic and episodic memory) and developmental 
period (childhood, adulthood, and recent life).
Methods
Procedure
Patients clinically diagnosed as suffering from PTSD 
(accident-related injuries, cancer, domestic violence) par-
ticipated in this study. They were all recruited from the Sina 
Hospital, Mahak (cancer foundation), and from psychiatric 
and psychological centers in Tehran, Iran. Before entering the 
study, patients were fully informed about its aims, scope, and 
procedures and gave written informed consent. Additionally, 
the local ethics committee approved the study, and the entire 
study was performed according to the rules laid down in the 
Declaration of Helsinki.
After a thorough psychiatric interview, all patients were 
psychopharmacologically treated with SSRIs, neuroleptics, 
or benzodiazepines (Table 1). Dosages were individually 
adapted to patients and kept constant throughout the study 
in order to achieve and maintain treatment efficacy. Next, 
patients were randomly assigned either to an intervention or 
control condition. At the beginning and at the end of the study 
10 weeks later, patients completed a series of questionnaires 
as described in more details below, and experts’ ratings were 
performed in parallel. In addition to the diagnostic interview, 
both groups had the autobiographical memory interview. 
After completion of the study, patients in the control condi-
tion received the same treatment as that provided for the 
intervention group. Psychologists and psychiatrists involved 
in the study and responsible for experts’ ratings were not 
aware of patients’ group assignment.
Table 1 Descriptive and statistical overview of patients’ sociodemographic dimensions and medication at baseline, separately by group 
(intervention versus control condition)
N Group Statistics
Intervention group Control group
20 20
age, years (standard deviation) 32.07 (5.76) 31.21 (6.10) t(38)=0.38, P0.78
sex (male/female) 5/15 7/13 χ2(df=1, N=40) =0.85, P0.35
civil status (single/married) 6/14 7/13 χ2(1) =0.19, P0.65
Medications
Benzodiazepines (yes/no) 12/8 10/10 χ2(1) 1.5, P0.1
antidepressants (yes/no) 18/2 16/4 χ2(1) 1.5, P0.1
Neuroleptics (yes/no) 6/14 9/11 χ2(1) 1.5, P0.1
Patients receiving one  
pharmacologic agent (yes/no)
20/0 20/0 –
Patients receiving two  
pharmacologic agents
9/11 11/9 χ2(1) 1.0, P0.1
Patients receiving three or more  
pharmacologic agents
3/17 2/18 χ2(1) 1.0, P0.1
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randomization
First, a ballot box containing two different colored chips 
was prepared (20 blue chips for the intervention, and 20 red 
chips for the control condition). A psychologist (FA) drew 
chips consecutively and assigned patients to either to the 
intervention or control condition. FA was also responsible 
for the psychotherapeutic intervention, though she was not 
further involved in experts’ ratings.
sample
Patients suffering from PTSD and attending the Sina 
Hospital, Mahak (cancer foundation), and other psychiatric 
and psychological centers in Tehran, Iran were approached 
regarding the study. The CONSORT flow chart (Figure 1) 
indicates how many patients were approached, and how 
many completed the study. Of the 76 patients approached, 
40 (52.63%) agreed to participate in the study. Further, 
12 patients, who were randomly assigned to the interven-
tion or the control condition, withdraw after randomization 
and baseline assessment; accordingly, 28 patients started 
the study. Of these, six (21.43%) were male (mean age: 
29.50 years, standard deviation: 4.97) and 22 (78.57%) were 
female (mean age: 32.23 years, standard deviation: 6.02; 
t[26]=1.02, P=0.32, d=0.496). Please note that to perform 
the statistical analysis, the intent-to-treat algorithm with the 
last observation carried forward procedure was performed, 
and not the per protocol algorithm (see also the “Statistical 
analysis” section at the end of the “Methods” section).
Figure 1 The CONSORT flow diagram shows the number of patients enrolled, randomly assigned to the study conditions, and finally analyzed.
Analyzed (n=14)
♦   Excluded from analysis (n=0)     
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Enrollment Assessed for eligibility (n=76)
Allocation 
Analysis 
Follow-up 
Randomized (n=40)
Excluded (n=36)
♦   Not meeting inclusion criteria (n=19)
♦   Declined to participate (n=14)
♦   Other reasons (n=3) 
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocated to intervention (n=20)
♦   Received allocated intervention (n=14)
♦   Did not receive allocated intervention
     (n=6)
Allocated to intervention (n=20)
♦   Received allocated intervention (n=14)
♦   Did not receive allocated intervention
     (n=6) 
Analyzed (n=14)
♦   Excluded from analysis (n=0)
Neuropsychiatric Disease and Treatment 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
399
cognitive behavior therapy in post-traumatic stress disorder
Inclusion criteria were as follows: 1) a diagnosis of PTSD 
according to the diagnostic criteria of the DSM-5;23 and 2) 
aged between 18 and 45 years. Exclusion criteria were the 
following: 1) further psychiatric comorbidities such as major 
depressive disorder, anxiety disorders, substance abuse 
(alcohol, drugs), psychosis, and personality disorders; 2) 
women who were pregnant or intending to get pregnant or 
who were breast-feeding; 3) known physical illness such as 
heart disease; and 4) patients already undergoing a psycho-
therapeutic treatment. Patients were also excluded if they 
decided to withdraw from the study (though without indicat-
ing the reasons).
Sample characteristics are reported separately for inter-
vention and control groups in Table 1.
No differences between the intervention and the control 
group were observed as regards sociodemographic variables 
and medications (types and number of medications; for 
symptoms at baseline for PTSD, depression, and anxiety, 
Table 2).
Materials
One questionnaire was employed, which covered demo-
graphic variables such as sex, age, civil status, educational 
level, and current employment.
symptoms of PTsD
To assess symptoms of PTSD, the Impact of Event Scale-
Revised24 questionnaire was employed. It consists of 22 items 
asking about PTSD symptoms such as avoidance, arousal, 
and unpleasant thought. Answers are given on 5-point Likert-
scales ranging from 0 (never) to 4 (extremely), with higher 
sum scores reflecting more severe symptoms (Cronbach’s 
alpha =0.92).
symptoms of depression
To assess symptoms of depression, the Beck Depression Inven-
tory25 questionnaire was employed. It consists of 21 items asking 
about symptoms of depression such as pessimism and negative 
thoughts, sadness, reduced incentives, and physiological prob-
lems. Answers are given on 4-point Likert-scales ranging from 
0 (never) to 3 (extremely), with higher sum scores reflecting 
more severe symptoms (Cronbach’s alpha =0.87).
symptoms of anxiety
To assess symptoms of anxiety, the Beck Anxiety Inventory26 
questionnaire was employed. It consists of 21 items asking 
about symptoms of anxiety such as worry, anxiety, and 
physiological problems. Answers are given on 4-point Likert-
scales ranging from 0 (never) to 3 (extremely), with higher 
sum scores reflecting more severe symptoms (Cronbach’s 
alpha =0.92).
assessing semantic and episodic memory 
performance
To assess autobiographical memory, both at baseline and 
at follow-up, an autobiographical memory interview27 was 
performed. The face-to-face interview consists of 52 items 
and assesses semantic and episodic memory performance 
separately for childhood, adulthood, and current life. Typi-
cal items are: “Mention three of your childhood friends’ 
or neighbors’ full names”, “Mention a memory form that 
course or that job”, and “Name a place you visited last 
Table 2 Descriptive and statistical overview of patients’ symptom-related dimensions, separated by group (intervention versus control 
condition) and time (baseline versus follow-up)
Time points
Baseline Follow-up Time Statistics
Group Group Group Time × group  
intervention
Intervention  
group
Control  
group
Intervention  
group
Control  
group
F (η2) F (η2) F (η2)
symptoms of depression 66.43 (5.26) 64.64 (5.58) 38.93 (2.92) 43.64 (4.29) 336.69*** (0.93) [l] 1.63 (0.059) [s] 6.05* (0.189) [l]
symptoms of anxiety 46.29 (6.39) 46.86 (6.81) 42.14 (4.85) 46.21 (5.79) 20.59*** (0.446) [l] 1.01 (0.041) [s] 11.21** (0.301) [l]
symptoms of PTsD
Total score 66.36 (4.81) 64.00 (5.11) 55.57 (4.77) 63.50 (5.68) 27.80*** (0.517) [l] 3.00 (0.102) [M] 23.09*** (0.470) [l]
avoidance 22.50 (3.92) 22.14 (4.09) 18.79 (2.75) 21.43 (2.90) 8.31* (0.242) [l] 1.16 (0.043) [s] 3.81 (0.128) [M]
intrusion 21.71 (3.69) 20.43 (3.34) 18.43 (2.71) 20.64 (2.56) 7.21* (0.251) [l] 0.025 (0.001) [s] 9.24** (0.262) [l]
hyperarousal 22.21 (1.63) 22.07 (1.14) 18.38 (2.65) 21.43 (2.17) 22.08*** (0.459) [l] 6.48* (0.199) [l] 11.26** (0.302) [l]
Notes: Degrees of freedom: always (1, 38); *P0.05; **P0.01; ***P0.001. effect sizes (η2): [s] = small effect; [M] = medium effect; [l] = large effect.
Abbreviation: PTsD, post-traumatic stress disorder.
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year.” Trained psychologists and psychiatrists not otherwise 
involved in the treatment and scoring assessed the semantic 
and episodic memory performance.
intervention
The intervention was conceptualized on the basis of Clark 
and Beck’s CBT for the treatment of PTSD28 and involved 
the following procedures. Trained and experienced psycho-
therapists (psychologists, psychiatrists) not involved in the 
experts’ ratings performed the intervention. Group sessions 
took place once per week for 60–90 minutes.
First session
The first session involves establishing a therapeutic 
relationship with the client: the therapist introduces and 
explains PTSD, together with its signs and symptoms; 
brochures are provided about the disease commensurate 
with the knowledge and educational level of clients. CBT 
is explained in relation to cognitive features of PTSD, 
including thoughts, negative beliefs and memories related 
to the event, negative emotions, and avoidance of trauma-
related memories.
second session
The second session involves assessment of thoughts and 
negative beliefs about PTSD and cognitive assessment and 
rehabilitation of PTSD including correction of erroneous 
assessments. It also includes modification and cognitive 
rehabilitation of incorrect assessments.
Third session
The third session involves cognitive restructuring with a 
focus on trauma and identification of beliefs and negative 
evaluations of clients, in cases of injury, and its consequences 
for explaining the emergence of PTSD.
Fourth session
The fourth session involves identifying and correcting 
a patient’s faulty thinking and assessment; modifying it 
through the use of techniques such as reviewing the evidence, 
analysis of profit and loss, and identifying and modifying 
cognitive errors; and setting homework.
Fifth session
The fifth session involves evaluating assignments related to 
the previous session, including the technique of reviewing the 
evidence, and explaining new techniques such as loss and 
profit techniques.
sixth and seventh session
The sixth and seventh session involve imagined flooding.
eighth and ninth session
The eighth and ninth session involve maladaptive cognitive 
and behavioral modification techniques through mindful-
ness training.
Tenth and closing session
The tenth and closing session include control of emotion 
through progressive muscle relaxation techniques with 
breathing regulation.
Individualized health plans were provided in sessions of 
1 hour per week in medical centers.
control condition
Once a week, patients in the control condition individually 
attended the center for a medical check. Further, medication 
regimen was asked about as well as possible side effects. 
Patients, however, were free to talk about their current life, 
concerns, and disorders. On doing so, we kept social contact 
with the professional hospital staff equal between the inter-
vention and control condition.
statistical analysis
All computations were performed per intention-to-treat 
with the last-observation-carried-forward (N=20 per 
group). A series of analyses of variance for repeated 
measures was performed with the factors “time” (base-
line, follow-up) and “group” (intervention versus control 
group), and the dependent variables of symptoms of 
PTSD, depression, anxiety, and memory performance. For 
analyses of variance, effect sizes are indicated with the 
partial eta squared (η2), with 0.059η20.01 indicating 
small, 0.139η20.06 indicating medium, and η20.14 
indicating large effect sizes. The level of significance 
was set at P0.05, and all statistics were processed using 
SPSS® 20.0 (IBM Corporation, Armonk, NY, USA) for 
Apple McIntosh®.
Results
All descriptive and statistical information (means, standard 
deviations, P-values, effect sizes) are reported in the tables 
and therefore not repeated in the text.
Table 2 gives a descriptive and statistical overview of 
symptom-related dimensions separately by group (inter-
vention versus control condition) and time (baseline versus 
follow-up). Symptoms of both depression and anxiety 
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decreased over time. No group differences were observed. 
The significant time by group interactions showed that symp-
toms of depression and anxiety decreased significantly more 
in the intervention than in the control group.
For PTSDs, total score, avoidance, intrusion, and hyper-
arousal decreased over time. For hyperarousal, the control 
group had significantly higher scores than the intervention 
group. Medium to large effect sizes were observed for the 
time by group interaction; PTSD scores decreased more over 
time in the intervention than in the control group (Table 2).
autobiographical memory
Table 3 gives a descriptive and statistical overview of 
 symptom-related dimensions separately by group (intervention 
versus control condition) and time (baseline versus follow-up).
For childhood memory there were no significant changes 
over time or between groups.
For adult memory (semantic and episodic) scores 
improved over time but more in the experimental group.
For Recent memory, scores improved over time but 
improved more in the experimental group.
For positive scores (general), scores increased over time 
but declined more in the experimental group.
For positive scores (specific), scores increased over time 
with a greater increase in the experimental group.
Discussion
The key findings of the present study are that additional CBT sig-
nificantly reduced symptoms of PTSD, depression, and anxiety 
among a sample of patients suffering from PTSD, as compared 
to those in a control condition. Moreover, results showed that 
CBT also improved autobiographical memory over time. The 
present study adds to the current literature in an important way in 
demonstrating the advantage of additional non-pharmacological 
treatments in patients suffering from PTSD; it significantly 
reduced symptoms and improved memory performance.
Two hypotheses were formulated, and these are now 
considered in turn. Our first hypothesis was that there would 
be greater symptom improvements in the intervention than 
the control group, and this hypothesis was fully supported. 
Accordingly, the present results are in accordance with 
a wealth of previous research that has shown a favorable 
influence of (additional) CBT in the treatment of PTSD, 
as compared to pharmacological treatment alone.10,12,17 
However, the present study expands on previous research 
in showing that a highly standardized group therapy for ten 
sessions over a period of 10 weeks improved symptoms of 
PTSD, depression, and anxiety.
Our second hypothesis was that additional CBT would 
also improve dimensions of autobiographical memory, and 
this was broadly supported. Specifically, for autobiographical 
memory performance for adulthood and the current period 
of life, the group by time interaction showed that additional 
CBT led to a significant improvement for semantic memory 
(but not episodic memory) for adult memory, whereas for 
recent memory, additional CBT improved episodic memory 
(but not semantic memory). To the best of our knowledge, 
similar findings have not so far been reported; accordingly 
the present study expands upon existing research on PTSD 
in demonstrating that highly standardized CBT intervention 
Table 3 Descriptive and statistical overview of patients’ memory performance, separated by group (intervention versus control 
condition) and time (baseline versus follow-up)
Time points
Baseline Follow-up Time Statistics
Group Group Group Time × group  
interaction
Intervention  
group
Control  
group
Intervention  
group
Control  
group
F (η2) F (η2) F (η2)
M (SD) M (SD)
childhood memory
semantic memory 16.18 (2.22) 15.64 (2.51) 16.21 (1.49) 15.79 (2.58) 0.32 (0.01) [s] 0.35 (0.0113) [s] 0.12 (0.004) [s]
episodic memory 3.68 (0.95) 4.04 (1.25) 3.85 (0.63) 4.18 (1.14) 1.88 (0.067) [s] 0.02 (0.001) [s] 0.85 (0.032) [s]
adult memory
semantic memory 16.280 (1.37) 15.39 (1.90) 17.04 (1.22) 15.05 (1.37) 10.73*** (0.292) [l] 6.03*** (0.188) [l] 4.36*** (0.144) [l]
episodic memory 4.10 (1.23) 3.68 (1.29) 4.71 (0.85) 3.89 (1.15) 14.54*** (0.359) [l] 3.33* (0.113) [M] 2.235 (0.079) [M]
recent memory
semantic memory 17.29 (2.68) 16.9 (3.07) 17.86 (2.21) 16.75 (2.87) 2.96* (0.102) [M] 3.79* (0.127) [M] 0.62 (0.023) [s]
episodic memory 4.00 (1.30) 3.29 (1.39) 4.57 (0.99) 3.32 (1.34) 9.37*** (0.265) [l] 7.29*** (0.219) [l] 4.39** (0.144) [l]
Notes: Degrees of freedom: always (1, 38); *P0.05; **P0.01; ***P0.001. effect sizes (η2): [s] = small effect; [M] = medium effect; [l] = large effect.
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has a positive influence not only on symptoms but also on 
autobiographical memory.
The present data do not allow any deeper understanding 
of the underlying cognitive–emotional and neurophysi-
ological mechanisms. However, the following hypotheses 
are advanced.
As regards the cognitive–emotional changes, we note that 
the CBT program was specifically targeted at changing and 
favorably modifying dysfunctional thoughts (see “Methods” 
section). Accordingly, we assume that patients in the inter-
vention group learned to restructure and positively alter their 
dysfunctional thoughts and emotions, which as a result reduced 
symptoms of depression, anxiety, and PTSD. To illustrate, by 
the second session, patients in the intervention group were 
already listing their thoughts and negative believes about PTSD 
and were evaluating the extent to which their behavior was 
causally associated with the dramatic event leading to PTSD. 
Likewise they were also evaluating the degree to which they 
were victims of the event, and the thoughts and feelings associ-
ated with it, and, in contrast, to what extent they could learn to 
manage, modify, and improve their thoughts. Connected to this, 
we believe that through the CBT intervention, patients became 
aware of their (unconscious) dysfunctional thoughts and beliefs 
and learned to evaluate the extent to which their thoughts and 
feelings were causally linked to the emergence and mainte-
nance of symptoms of depression, anxiety, and PTSD, and that 
they learned how to cope with their current situation. On the flip 
side, we note that favorable changes in symptoms and memory 
were also observed in the control group. Therefore, the present 
data also show evidence that a mere psychopharmacological 
treatment leads to improvements both in symptoms and in 
memory (see also Polak et al,10 Ipser et al14).
To explain PTSD from a neuroendocrinologic point of 
view, it is assumed that an increase in the adrenergic activity 
of the central nervous system (CNS) is associated with the 
pathophysiology of PTSD and more specifically with sleep 
disorders.29 In fact, it seems that many of the symptoms of 
PTSD could be pathophysiologically caused or intensified 
by an increase in the adrenergic activity of the CNS.29,30 
Such an increase in adrenergic activity can lead to increased 
secretion of norepinephrine and to elevated responsiveness 
of receptors to norepinephrine. Accordingly, though highly 
speculative, we suggest that CBT was able to decrease the 
adrenergic activity in the CNS. Likewise, though unfortu-
nately not assessed, we believe that CBT was able to improve 
patients’ sleep, which in turn may have led to improvement 
in  symptoms. Indeed, there is a wealth of evidence for a close 
association between symptoms of depression and anxiety and 
poor sleep.31–33 Accordingly, it is highly conceivable that the 
sleep of patients in the intervention group improved, and in 
a sort of positive feedback loop this also ameliorated symp-
toms of depression, anxiety, and PTSD. Indeed, as regards 
the association between sleep and PTSD, specific alpha1-
receptor-blockers such as prazosin and specific H1-receptor 
blockers such as hydroxyzine reduce occurrence of night-
mares and sleep disturbances among patients suffering from 
PTSD as compared to a control condition.35
Despite the intriguing results, several limitations warn 
against overgeneralizing the results. First, the sample size 
was rather small and there were drop-outs. However, the 
effect-size calculations which we report are not sensitive to 
sample sizes. Second, the age range was limited to below 
45 years of age; we did this to keep the sample homogeneous 
and to avoid possible confounders such as age. Nevertheless, 
we acknowledge, that also enrolling elderly patients would 
have been advisable, especially given that an emphasis of 
the study was on autobiographical memory, which would be 
expected to be worse, and therefore possible more amenable 
to treatment, in older subjects. Third, sleep was not assessed 
though there is striking evidence that improved sleep is 
associated with improvements in symptoms of depression, 
anxiety, and PTSD.32–34 Accordingly, it remains unclear to 
what extend sleep changes might explain the variance in 
symptom improvements. Future studies should therefore 
assess sleep both subjectively and objectively. Fourth, no 
neuroendocrine assessment was performed; such assessment 
might have provided more insight into the underlying neu-
roendocrine mechanisms.36,37 Fifth, no follow-up assessment 
was performed; this would have allowed investigation of the 
longer-term impact of CBT. Last, it is possible that the present 
pattern of results is due to unassessed variables, which might 
have biased two or more variables in the same direction.
Conclusion
The present study showed that an additional and highly stan-
dardized CBT program had a favorable influence on symptoms 
of PTSD, depression, and anxiety, and on autobiographical 
memory among patients suffering from PTSD, as compared 
to a control group treated pharmacologically only.
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